Replimune Group, Inc. (REPL)
$15.45-$0.15 (-0.96%) Today
Andrew Schwendenman - OfficerReplimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 2,736,340 | $33.00M |
| Open-market sale | 6 | 91,124 | $1.15M |
| Bona-fide gift | 1 | 50,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
38 Form 4 filings on record, the earliest from Nov 20, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sushil Patel - Officer | Open-market sale | Common Stock | 10,000 | $11.13 | $111K | |
| Christopher Sarchi - Officer | Open-market sale | Common Stock | 5,208 | $9.10 | $47K | |
| Konstantinos Xynos - Officer | Open-market sale | Common Stock | 7,248 | $9.10 | $66K | |
| Emily Luisa Hill - Officer | Open-market sale | Common Stock | 9,154 | $5.37 | $49K | |
| Joseph P. Slattery - Director | Grant or award | Stock Option (right to buy) | 32,000 | $0.00 | - | |
| Sushil Patel - Officer | Open-market sale | Common Stock | 10,000 | $12.42 | $124K | |
| Konstantinos Xynos - Officer | Open-market sale | Common Stock | 7,246 | $10.78 | $78K | |
| Christopher Sarchi - Officer | Open-market sale | Common Stock | 5,207 | $10.78 | $56K |
This is as far as the anonymous view goes. Create a free account for all 38 REPL filings on record.
Replimune Group, Inc. (REPL) had 8 insider filings in the last 90 days, with the most recent on 2026-08-24. The full record for REPL runs to 38 Form 4 filings, the earliest from 2024-11-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
2 insider purchases of REPL were filed in the last 90 days, totaling $33.00M.
6 insider sales of REPL were filed in the last 90 days, totaling $1.15M.
This page tracks REPL Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add REPL to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
